Landmark Healthcare Anticompetition Case: News and Guidance From AMDR
The May 2025 jury verdict in Innovative Health, LLC v. Biosense Webster, Inc. is a watershed moment in the commercial device reprocessing, healthcare procurement, and broader medtech industries. Evidence and testimony entered during the trial exposed the anticompetitive practices the Johnson & Johnson MedTech unit used to undermine AMDR-member, regulated reprocessing companies – and how these practices inflated healthcare costs, undermined hospital choice, and risked compromising device quality.
AMDR invites clinicians, hospital procurement staff, regulators, journalists, and the public to review our news releases and statements about the case. We also direct hospitals to our Action Alerts, which provide practical guidance on how to withstand misinformation, coercion, and other anti-reprocessing conduct from certain OEMs.
Have you witnessed anti-reprocessing conduct? Please report it.
In Innovative Health v. Biosense Webster, the court banned specific, common anti-reprocessing tactics—for example, blocking reprocessed devices with “kill chips” or tying clinical support to purchasing OEM devices. To ensure compliance with the terms of the injunction, the court ordered that AMDR (as designated by Innovative Health) establish an anonymous hotline to collect reports of potential violations.
- If you suspect your vendor may be violating the injunction, please consider making a report to our anonymous hotline:
Hotline (24/7): 855-893-7002
Web form: report.syntrio.com/reprocessing
Our third-party hotline protects you with advanced encryption and anonymity techniques. Neither AMDR nor anyone else will not be able to determine your identity unless you grant us permission.
- Or, to report general anti-reprocessing conduct, please use our reporting form (click here to download).
About the Case
Tools and Resources for Hospitals
AMDR’s Resources for Hospitals page includes information about common OEM anti-reprocessing tactics and practical tools for health systems to protect their reprocessing programs—like a ready-to-use Reprocessing Policy Template and a Procurement Checklist to guide purchasing decisions and supplier contracts.
The page also contains resources about how hospitals benefit from and can optimize their reprocessing programs.
AMDR’s Action Alerts and Technical Tips provide awareness and guidance on important industry developments that could impact your facility’s ability to deliver affordable, sustainable healthcare. Some of our Alerts are directly inspired by what was exposed in the case:
August 28, 2025 | Court Prohibits Certain Anti-Reprocessing Tactics Following Innovative Health v. Biosense Webster Verdict
A federal court has issued a permanent injunction barring Johnson & Johnson’s Biosense Webster unit from interfering with reprocessing, following a trial in which the jury found the company liable for unlawful tying and monopolization. The court has barred Biosense from tying case support to device purchases, disabling reprocessed devices with chips, and hoarding used devices to cut off reprocessors’ supply.
This Action Alert explains the ruling, what hospitals should watch for, and how to report violations.
June 30, 2025 | Reporting OEM Anti-Reprocessing Interference Following Innovative Health v. Biosense Webster Verdict
A federal jury has found a major OEM liable for unlawful tying and monopolization. AMDR has created a short form so hospital staff, supply chains, and reprocessors can report anti-reprocessing interference and route evidence to the right authorities. Reports may be submitted anonymously.
Read the Action Alert for a checklist of what to document, who to notify internally, and the downloadable reporting form.
AMDR has created a short form so hospital staff, supply chains, and reprocessors can report anti-reprocessing interference and route evidence to the right authorities. Reports may be submitted anonymously. Click here to download the form.
